Trial Profile
A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; Semustine
- Indications Astrocytoma; Glioblastoma
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.; Schering-Plough
- 13 Oct 2008 New trial record.